Clinical characteristics of Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions induced by immune checkpoint inhibitors
The Oncologist · 04.06.2025 · 30 (6)
DOI: 10.1093/oncolo/oyaf143 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 10.06.2025. Verfasst von Ziliang Zheng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China. Hauptthemen laut MEDLINE: Stevens-Johnson Syndrome, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have demonstrated significant therapeutic benefits but are also associated with skin-related adverse reactions. The specific characteristics of severe adverse reactions caused by ICIs remain unclear.
Objective
To investigate the disease characteristics of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN)-like reactions induced by ICIs.
Methods
Cases of ICI-induced SJS/TEN were collected from PubMed, CNKI, Wanfang Data Knowledge Service Platform, and Guangdong Provincial People’s Hospital, with a search time span ranging from March 2011 to January 31, 2024.
Results
A total of 110 cases of SJS, TEN, and overlapping SJS/TEN were analyzed, with a male predominance (62%). Mucous membrane involvement was observed in 71 patients (66%), though less frequently than in classic SJS/TEN. The mean latency period was 64 days, varying by subtype (105 days for SJS and 53 days for TEN). Combination therapy with ICIs was associated with a higher mortality risk (P = .029). Deceased patients exhibited shorter latency periods (mean 30.3 days) and more severe mucosal involvement (up to 100%), although the differences were not statistically significant. Systemic glucocorticoid therapy was the cornerstone of treatment for SJS/TEN-like reactions. The addition of immunoglobulin showed a trend toward improved outcomes but did not significantly affect mortality or cure rates compared to glucocorticoid monotherapy. The combination of systemic glucocorticoids and antibiotics demonstrated a promising trend, with a higher proportion of patients in the improvement/cure group using this regimen (P = .085).
Conclusions
This study summarizes the clinical characteristics of ICI-induced SJS/TEN-like reactions, providing insights into their features and potential treatment strategies for severe skin-related adverse events induced by ICIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
- Department of Dermatology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.
ORCID-Profile: Ziliang Zheng, Zhu Shen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zheng, Z., & Shen, Z. (2025). Clinical characteristics of Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions induced by immune checkpoint inhibitors. The Oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf143
Vancouver
Zheng Z, Shen Z. Clinical characteristics of Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions induced by immune checkpoint inhibitors. The Oncologist. 2025;30(6). doi:10.1093/oncolo/oyaf143
BibTeX
@article{Zheng2025,
author = {Zheng, Ziliang and Shen, Zhu},
title = {Clinical characteristics of Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions induced by immune checkpoint inhibitors},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {6},
doi = {10.1093/oncolo/oyaf143}
}
EUVIMED